コクシジオイデス症治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Coccidioidomycosis - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0784
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:76
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Coccidioidomycosis – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Coccidioidomycosis – Pipeline Review, H1 2020, provides an overview of the Coccidioidomycosis (Infectious Disease) pipeline landscape.

Coccidioidomycosis, also called Valley fever, is an infection caused by the fungus Coccidioides. Symptoms includefever, cough, chest pain, chills, headache, fatigue and joint aches. Risk factors include weakened immune system,age, pregnancy, race and environmental exposure. Treatment includes antifungal medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Coccidioidomycosis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Coccidioidomycosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coccidioidomycosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coccidioidomycosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Coccidioidomycosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Coccidioidomycosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Coccidioidomycosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Coccidioidomycosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Coccidioidomycosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Coccidioidomycosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Coccidioidomycosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Coccidioidomycosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Coccidioidomycosis – Overview
Coccidioidomycosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Coccidioidomycosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Coccidioidomycosis – Companies Involved in Therapeutics Development
Acea Biotech Inc
Amplyx Pharmaceuticals Inc
F2G Ltd
Mycovia Pharmaceuticals Inc
Scynexis Inc
Valley Fever Solutions Inc
Coccidioidomycosis – Drug Profiles
Amphotericin B sodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coccidioidomycosis vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosmanogepix – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibrexafungerp citrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nikkomycin Z – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olorofim – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oteseconazole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1598 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coccidioidomycosis – Dormant Projects
Coccidioidomycosis – Product Development Milestones
Featured News & Press Releases
Oct 24, 2019: SCYNEXIS expands FURI protocol to a broader range of refractory serious fungal infections, building on Ibrexafungerp’s positive data and favorable toxicology profile observed to date
Sep 09, 2019: FDA grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for seven different indications
Jun 07, 2018: Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
Jul 13, 2017: FDA Grants Fast Track Designation to VT-1598 for Treatment of Valley Fever
May 17, 2017: Viamet To Present Data on VT-1598 at The American Society for Microbiology’s ASM Microbe 2017 Conference
Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
Sep 15, 2016: FDA Grants QIDP Designation to VT-1598 for Treatment of Valley Fever
Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections
May 25, 2016: Viamet Receives Orphan Drug Designation from the FDA for VT-1598 for the Treatment of Coccidioidomycosis
May 20, 2015: Viamet Announces NIH Grant for Compounds Directed at Valley Fever
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Coccidioidomycosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Coccidioidomycosis - Pipeline by Acea Biotech Inc, H1 2020
Coccidioidomycosis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2020
Coccidioidomycosis - Pipeline by F2G Ltd, H1 2020
Coccidioidomycosis - Pipeline by Mycovia Pharmaceuticals Inc, H1 2020
Coccidioidomycosis - Pipeline by Scynexis Inc, H1 2020
Coccidioidomycosis - Pipeline by Valley Fever Solutions Inc, H1 2020
Coccidioidomycosis - Dormant Projects, H1 2020

【掲載企業】

Acea Biotech Inc
Amplyx Pharmaceuticals Inc
F2G Ltd
Mycovia Pharmaceuticals Inc
Scynexis Inc
Valley Fever Solutions Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[コクシジオイデス症治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆